

**ASX ANNOUNCEMENT**

2 May 2023

## Initial Director's Interest Notice – Cheryl Maley

**Clarity Pharmaceuticals** (ASX: CU6) ("Clarity", "the Company"), a clinical stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for children and adults with cancer, presents here the *Appendix 3X - Initial Director's Interest Notice* for Ms Cheryl Maley.

Ms Maley commenced on 1 February 2023. Due to an administrative oversight by the Company the Notice was not released in the required period following her commencement.

### About Clarity Pharmaceuticals

Clarity is a clinical stage radiopharmaceutical company focused on the treatment of serious disease. The Company is a leader in innovative radiopharmaceuticals, developing targeted copper theranostics based on its SAR Technology Platform for the treatment of cancer in children and adults.

[www.claritypharmaceuticals.com](http://www.claritypharmaceuticals.com)

### For more information, please contact:

**Clarity Pharmaceuticals**

Dr Alan Taylor

**Executive Chairman**

[ataylor@claritypharm.com](mailto:ataylor@claritypharm.com)

Catherine Strong

**Investor/Media Relations**

[cstrong@citadelmagnus.com](mailto:cstrong@citadelmagnus.com)

+61 406 759 268

*This announcement has been authorised for release by the Executive Chairman.*

# Appendix 3X

## Initial Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/9/2001.

<b>Name of entity</b>	<b>Clarity Pharmaceuticals Ltd</b>
<b>ABN</b>	<b>36 143 005 341</b>

We (the entity) give ASX the following information under listing rule 3.19A.1 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Cheryl Ann Maley
<b>Date of appointment</b>	1 February 2023

### Part 1 - Director's relevant interests in securities of which the director is the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Nil
-----

+ See chapter 19 for defined terms.

## Appendix 3X Initial Director's Interest Notice

---

### Part 2 – Director's relevant interests in securities of which the director is not the registered holder

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

<b>Name of holder &amp; nature of interest</b> Note: Provide details of the circumstances giving rise to the relevant interest.	<b>Number &amp; class of Securities</b>
N/A	N/A

### Part 3 – Director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	N/A
<b>Name of registered holder (if issued securities)</b>	N/A
<b>No. and class of securities to which interest relates</b>	N/A

---

+ See chapter 19 for defined terms.